Netarsudil

BreastfeedingPediatric
  • TRADE NAME: Rhopressa (Aerie)
  • INDICATIONS: Reduction of elevated intraocular pressure in open angle glaucoma or ocular hypertension
  • CLASS: Rho kinase inhibitor
  • HALF-LIFE: N/A

FDA APPROVAL DATE: 12/18/2017

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A
No available data to inform drug-associated risk

Our database has 10 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

OCULAR
LOCAL


Page last updated 04/09/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric